Exome Asset Management
Latest statistics and disclosures from Exome Asset Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are GH, PRAX, TGTX, COGT, IONS, and represent 26.79% of Exome Asset Management's stock portfolio.
- Added to shares of these 10 stocks: TGTX (+$9.1M), ABVX (+$6.2M), QURE, AZN, VKTX, OCUL, EQ, ASND, NKTR, CLPT.
- Started 15 new stock positions in NKTR, REPL, CLPT, ABVX, DRUG, OCUL, AZN, VKTX, CMPX, ASND. CAI, EQ, QURE, GERN, TGTX.
- Reduced shares in these 10 stocks: , PRAX (-$6.1M), ELVN (-$6.1M), RLAY, ELV, Cytokinetics, CYTK, BBIO, Apellis Pharmaceuticals, Beigene Ltd call.
- Sold out of its positions in Alumis, ELV, Apellis Pharmaceuticals, AVTX, Beigene Ltd call, Centessa Pharmaceuticals, Compass Therapeutics, Cytokinetics, FDMT, Ideaya Biosciences. LPCN, Liquidia Technologies, NXTC, PALI, XBI, Soleno Therapeutics, Travere Therapeutics, Wave Life Sciences Ltd put.
- Exome Asset Management was a net seller of stock by $-58M.
- Exome Asset Management has $162M in assets under management (AUM), dropping by -16.16%.
- Central Index Key (CIK): 0002011932
Tip: Access up to 7 years of quarterly data
Positions held by Exome Asset Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Exome Asset Management
Exome Asset Management holds 52 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Guardant Health (GH) | 6.2 | $10M | -18% | 68k | 150.03 |
|
| Praxis Precision Medicines I Com New (PRAX) | 5.6 | $9.1M | -40% | 27k | 334.79 |
|
| Tg Therapeutics (TGTX) | 5.6 | $9.1M | NEW | 165k | 54.94 |
|
| Cogent Biosciences (COGT) | 5.0 | $8.1M | -24% | 211k | 38.70 |
|
| Ionis Pharmaceuticals (IONS) | 4.3 | $7.0M | -19% | 88k | 79.29 |
|
| Eli Lilly & Co. (LLY) | 4.1 | $6.6M | -21% | 5.5k | 1199.43 |
|
| Abivax Sa Sponsored Ads (ABVX) | 3.9 | $6.2M | NEW | 47k | 133.26 |
|
| Alumis (ALMS) | 3.5 | $5.8M | -26% | 204k | 28.14 |
|
| Cytokinetics Com New (CYTK) | 3.2 | $5.1M | -42% | 60k | 85.19 |
|
| Enliven Therapeutics (ELVN) | 3.1 | $5.1M | -54% | 100k | 50.75 |
|
| Vera Therapeutics Cl A (VERA) | 2.6 | $4.2M | -15% | 97k | 42.91 |
|
| UnitedHealth (UNH) | 2.5 | $4.0M | -25% | 9.6k | 415.63 |
|
| 10x Genomics Cl A Com (TXG) | 2.4 | $3.9M | -33% | 103k | 38.34 |
|
| Natera (NTRA) | 2.3 | $3.7M | -26% | 14k | 271.45 |
|
| Uniqure Nv SHS (QURE) | 2.3 | $3.7M | NEW | 81k | 46.06 |
|
| Rhythm Pharmaceuticals (RYTM) | 2.2 | $3.6M | -20% | 32k | 111.03 |
|
| Maze Therapeatics (MAZE) | 2.1 | $3.4M | +29% | 115k | 29.84 |
|
| Monte Rosa Therapeutics (GLUE) | 2.0 | $3.3M | -23% | 137k | 24.20 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 2.0 | $3.2M | -22% | 167k | 19.47 |
|
| Alkermes SHS (ALKS) | 2.0 | $3.2M | -27% | 61k | 52.40 |
|
| Liquidia Corporation Com New (LQDA) | 1.9 | $3.1M | -14% | 39k | 79.73 |
|
| United Therapeutics Corporation (UTHR) | 1.8 | $2.9M | -23% | 5.4k | 541.83 |
|
| Glaukos (GKOS) | 1.7 | $2.8M | -4% | 20k | 139.76 |
|
| Arrowhead Pharmaceuticals (ARWR) | 1.6 | $2.6M | -29% | 32k | 81.51 |
|
| Agios Pharmaceuticals (AGIO) | 1.6 | $2.6M | -43% | 71k | 37.11 |
|
| Crescent Biopharma (CBIO) | 1.4 | $2.3M | -16% | 128k | 18.00 |
|
| Astrazeneca Ord (AZN) | 1.4 | $2.3M | NEW | 12k | 187.14 |
|
| Boston Scientific Corporation (BSX) | 1.3 | $2.1M | 48k | 42.68 |
|
|
| Adagene Ads (ADAG) | 1.3 | $2.1M | -33% | 488k | 4.20 |
|
| Penumbra (PEN) | 1.2 | $2.0M | 6.3k | 315.75 |
|
|
| Intuitive Surgical Com New (ISRG) | 1.2 | $2.0M | -22% | 4.9k | 397.68 |
|
| Viking Therapeutics (VKTX) | 1.2 | $1.9M | NEW | 48k | 39.01 |
|
| Ocular Therapeutix (OCUL) | 1.1 | $1.8M | NEW | 182k | 9.82 |
|
| Equillium (EQ) | 1.1 | $1.8M | NEW | 553k | 3.20 |
|
| Ascendis Pharma A/s Ord Shs (ASND) | 1.1 | $1.8M | NEW | 6.6k | 266.72 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 1.1 | $1.7M | -21% | 185k | 9.38 |
|
| Cytomx Therapeutics (CTMX) | 1.1 | $1.7M | -11% | 460k | 3.75 |
|
| Verastem Com New (VSTM) | 1.0 | $1.6M | -32% | 429k | 3.82 |
|
| Nektar Therapeutics Com New (NKTR) | 1.0 | $1.6M | NEW | 22k | 69.81 |
|
| Clearpoint Neuro (CLPT) | 0.9 | $1.5M | NEW | 84k | 17.84 |
|
| Insmed Com Par $.01 (INSM) | 0.9 | $1.5M | -47% | 14k | 106.62 |
|
| Caris Life Sciences (CAI) | 0.9 | $1.4M | NEW | 78k | 17.82 |
|
| Bridgebio Pharma (BBIO) | 0.8 | $1.4M | -72% | 18k | 74.48 |
|
| Zenas Biopharma (ZBIO) | 0.8 | $1.3M | -35% | 52k | 25.38 |
|
| Novabridge Biosciences Sponsored Ads (NBP) | 0.7 | $1.1M | 577k | 1.95 |
|
|
| Establishment Labs Holdings Ord (ESTA) | 0.7 | $1.1M | 13k | 85.81 |
|
|
| Relay Therapeutics (RLAY) | 0.5 | $889k | -82% | 48k | 18.71 |
|
| Geron Corporation (GERN) | 0.5 | $799k | NEW | 624k | 1.28 |
|
| Bright Minds Biosciences Com New (DRUG) | 0.4 | $710k | NEW | 10k | 70.20 |
|
| Compass Therapeutics (CMPX) | 0.4 | $605k | NEW | 276k | 2.19 |
|
| Replimune Group (REPL) | 0.3 | $447k | NEW | 40k | 11.07 |
|
| Arbutus Biopharma (ABUS) | 0.1 | $241k | -33% | 50k | 4.80 |
|
Past Filings by Exome Asset Management
SEC 13F filings are viewable for Exome Asset Management going back to 2023
- Exome Asset Management 2026 Q2 filed Aug. 14, 2026
- Exome Asset Management 2026 Q1 filed May 15, 2026
- Exome Asset Management 2025 Q4 filed Feb. 13, 2026
- Exome Asset Management 2025 Q3 filed Nov. 14, 2025
- Exome Asset Management 2025 Q2 restated filed Aug. 15, 2025
- Exome Asset Management 2025 Q1 restated filed May 16, 2025
- Exome Asset Management 2025 Q1 filed May 15, 2025
- Exome Asset Management 2024 Q4 filed Feb. 14, 2025
- Exome Asset Management 2024 Q3 amended filed Dec. 13, 2024
- Exome Asset Management 2024 Q2 restated filed Oct. 3, 2024
- Exome Asset Management 2024 Q2 filed Aug. 14, 2024
- Exome Asset Management 2024 Q1 filed May 15, 2024
- Exome Asset Management 2023 Q4 filed Feb. 15, 2024